ArticleScientific reports2026
A deep learning approach to assess transendothelial cell trafficking performance.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transendothelial migration (TEM), is a complex, multistep process impacted by diseases like autoimmune disorders and cancer. Deciphering aspects of the process enhances our understanding and possibilities for disease treatments. The extent to which this potential can be leveraged is often limited due to conventional assays neither accurately mimicking specific in vivo conditions like sheer stress nor visualizing the whole transmigration cascade, hence missing distinct mechanisms. Flow-based adhesion assays overcome these limitations and allow the use of various endothelial cells from different tissues with distinct properties. So far, a broader and translational assay application is hampered by potential operator-based bias/lack of standardization, as well as poor scalability due to time-consuming manual analysis. In this study, we successfully combined this assay with AI-based analysis including subsequent classification of cell-transmigration phases by a Keras/TensorFlow-based deep learning model. Trained on healthy-donor and pancreatic cancer patient-derived T cells, the model achieved a high accuracy of 91.6 % in identifying/categorizing cell transmigration, surpassing the currently accepted 80 %-threshold, therefore qualifying as a fast, standardized AI-based live-cell imaging tool. Additionally, its architecture grants highly convenient reconfiguration for various disease-model investigations. Hence, by combining an affordable and simplistic, yet potent live-cell-imaging technique with a comprehensive AI-approach, we have established a powerful tool which allows for integrating TEM-assays into various disease models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.